Instem PLC
LSE:INS
Intrinsic Value
Instem Plc engages in the provision of information technology solutions and services to the global health and life sciences community. [ Read More ]
The intrinsic value of one INS stock under the Base Case scenario is 944.91 GBX. Compared to the current market price of 830 GBX, Instem PLC is Undervalued by 12%.
Valuation Backtest
Instem PLC
Run backtest to discover the historical profit from buying and selling INS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Instem PLC
Current Assets | 24.2m |
Cash & Short-Term Investments | 8.4m |
Receivables | 15.4m |
Other Current Assets | 322k |
Non-Current Assets | 59.5m |
PP&E | 1.5m |
Intangibles | 58m |
Other Non-Current Assets | 14k |
Current Liabilities | 25.5m |
Accounts Payable | 4.6m |
Short-Term Debt | 1m |
Other Current Liabilities | 19.9m |
Non-Current Liabilities | 3.5m |
Long-Term Debt | 322k |
Other Non-Current Liabilities | 3.2m |
Earnings Waterfall
Instem PLC
Revenue
|
60.4m
GBP
|
Operating Expenses
|
-54.1m
GBP
|
Operating Income
|
6.3m
GBP
|
Other Expenses
|
-2.9m
GBP
|
Net Income
|
3.4m
GBP
|
Free Cash Flow Analysis
Instem PLC
What is Free Cash Flow?
INS Profitability Score
Profitability Due Diligence
Instem PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Instem PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
INS Solvency Score
Solvency Due Diligence
Instem PLC's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Score
Instem PLC's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INS Price Targets Summary
Instem PLC
According to Wall Street analysts, the average 1-year price target for INS is 1 023 GBX .
Shareholder Return
INS Price
Instem PLC
Average Annual Return | 44.66% |
Standard Deviation of Annual Returns | 27.58% |
Max Drawdown | -37% |
Market Capitalization | 190m GBX |
Shares Outstanding | 24 053 400 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Instem Plc engages in the provision of information technology solutions and services to the global health and life sciences community. The company is headquartered in Stone, Staffordshire and currently employs 304 full-time employees. The company went IPO on 2010-10-13. The firm operates through four segments: Study Management, Regulatory Solutions, In Silico Solutions and Clinical Trials Acceleration. Its Study Management Solutions is a software that enables organizations to collect, review, manage and report discovery and preclinical report. Its Regulatory Solutions is a software, outsourced services and consultancy for managing, storing, sharing, submitting and maintaining information compliant with agency regulations. The firm's In Silico Solutions enables researchers to generate scientific insights through identification, extraction and analysis of information. Its Clinical Trials Acceleration Solutions is a technology solution and consulting service to facilitate data integration, statistics, analytics and insights for companies any size or stage of clinical trial analysis.
Contact
IPO
Employees
Officers
The intrinsic value of one INS stock under the Base Case scenario is 944.91 GBX.
Compared to the current market price of 830 GBX, Instem PLC is Undervalued by 12%.